EVI1 splice variants modulate functional responses in ovarian cancer cells

Punashi Dutta, Tuyen Bui, Kyle A. Bauckman, Khandan Keyomarsi, Gordon Mills, Meera Nanjundan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Amplification of 3q26.2, found in many cancer lineages, is a frequent and early event in ovarian cancer. We previously defined the most frequent region of copy number increase at 3q26.2 to EVI1 (ecotropic viral integration site-1) and MDS1 (myelodysplastic syndrome 1) (aka MECOM), an observation recently confirmed by the cancer genome atlas (TCGA). MECOM is increased at the DNA, RNA, and protein level and likely contributes to patient outcome. Herein, we report that EVI1 is aberrantly spliced, generating multiple variants including a Del190-515 variant (equivalent to previously reported) expressed in >90% of advanced stage serous epithelial ovarian cancers. Although EVI1Del190-515 lacks ∼70% of exon 7, it binds CtBP1 as well as SMAD3, important mediators of TGFβ signaling, similar to wild type EVI1. This contrasts with EVI1 1-268 which failed to interact with CtBP1. Interestingly, the EVI1Del190-515 splice variant preferentially localizes to PML nuclear bodies compared to wild type and EVI1Del427-515. While wild type EVI1 efficiently repressed TGFβ-mediated AP-1 (activator protein-1) and plasminogen activator inhibitor-1 (PAI-1) promoters, EVI1Del190-515 elicited a slight increase in both promoter activities. Expression of EVI1 and EVI1Del427-515 (but not EVI1Del190-515) in OVCAR8 ovarian cancer cells increased cyclin E1 LMW expression and cell cycle progression. Furthermore, knockdown of specific EVI1 splice variants (both MDS1/EVI1 and EVI1Del190-515) markedly increased claudin-1 mRNA and protein expression in HEY ovarian and MDA-MB-231 breast cancer cells. Changes in claudin-1 were associated with alterations in specific epithelial-mesenchymal transition markers concurrent with reduced migratory potential. Collectively, EVI1 is frequently aberrantly spliced in ovarian cancer with specific forms eliciting altered functions which could potentially contribute to ovarian cancer pathophysiology.

Original languageEnglish (US)
Pages (from-to)647-668
Number of pages22
JournalMolecular Oncology
Volume7
Issue number3
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Virus Integration
Ovarian Neoplasms
Claudin-1
Myelodysplastic Syndromes
Claudins
Cyclins
Epithelial-Mesenchymal Transition
Atlases
Plasminogen Activator Inhibitor 1
Transcription Factor AP-1
Exons
Neoplasms
Cell Cycle
Observation
Genome
RNA
Breast Neoplasms

Keywords

  • Claudin-1
  • Cyclin E1
  • EMT
  • EVI1
  • Motility
  • Ovarian cancer
  • Splice variants
  • TGFβ

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cancer Research

Cite this

EVI1 splice variants modulate functional responses in ovarian cancer cells. / Dutta, Punashi; Bui, Tuyen; Bauckman, Kyle A.; Keyomarsi, Khandan; Mills, Gordon; Nanjundan, Meera.

In: Molecular Oncology, Vol. 7, No. 3, 01.01.2013, p. 647-668.

Research output: Contribution to journalArticle

Dutta, P, Bui, T, Bauckman, KA, Keyomarsi, K, Mills, G & Nanjundan, M 2013, 'EVI1 splice variants modulate functional responses in ovarian cancer cells', Molecular Oncology, vol. 7, no. 3, pp. 647-668. https://doi.org/10.1016/j.molonc.2013.02.008
Dutta, Punashi ; Bui, Tuyen ; Bauckman, Kyle A. ; Keyomarsi, Khandan ; Mills, Gordon ; Nanjundan, Meera. / EVI1 splice variants modulate functional responses in ovarian cancer cells. In: Molecular Oncology. 2013 ; Vol. 7, No. 3. pp. 647-668.
@article{879d200a106c476bbe5e9d774d0a3c69,
title = "EVI1 splice variants modulate functional responses in ovarian cancer cells",
abstract = "Amplification of 3q26.2, found in many cancer lineages, is a frequent and early event in ovarian cancer. We previously defined the most frequent region of copy number increase at 3q26.2 to EVI1 (ecotropic viral integration site-1) and MDS1 (myelodysplastic syndrome 1) (aka MECOM), an observation recently confirmed by the cancer genome atlas (TCGA). MECOM is increased at the DNA, RNA, and protein level and likely contributes to patient outcome. Herein, we report that EVI1 is aberrantly spliced, generating multiple variants including a Del190-515 variant (equivalent to previously reported) expressed in >90{\%} of advanced stage serous epithelial ovarian cancers. Although EVI1Del190-515 lacks ∼70{\%} of exon 7, it binds CtBP1 as well as SMAD3, important mediators of TGFβ signaling, similar to wild type EVI1. This contrasts with EVI1 1-268 which failed to interact with CtBP1. Interestingly, the EVI1Del190-515 splice variant preferentially localizes to PML nuclear bodies compared to wild type and EVI1Del427-515. While wild type EVI1 efficiently repressed TGFβ-mediated AP-1 (activator protein-1) and plasminogen activator inhibitor-1 (PAI-1) promoters, EVI1Del190-515 elicited a slight increase in both promoter activities. Expression of EVI1 and EVI1Del427-515 (but not EVI1Del190-515) in OVCAR8 ovarian cancer cells increased cyclin E1 LMW expression and cell cycle progression. Furthermore, knockdown of specific EVI1 splice variants (both MDS1/EVI1 and EVI1Del190-515) markedly increased claudin-1 mRNA and protein expression in HEY ovarian and MDA-MB-231 breast cancer cells. Changes in claudin-1 were associated with alterations in specific epithelial-mesenchymal transition markers concurrent with reduced migratory potential. Collectively, EVI1 is frequently aberrantly spliced in ovarian cancer with specific forms eliciting altered functions which could potentially contribute to ovarian cancer pathophysiology.",
keywords = "Claudin-1, Cyclin E1, EMT, EVI1, Motility, Ovarian cancer, Splice variants, TGFβ",
author = "Punashi Dutta and Tuyen Bui and Bauckman, {Kyle A.} and Khandan Keyomarsi and Gordon Mills and Meera Nanjundan",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.molonc.2013.02.008",
language = "English (US)",
volume = "7",
pages = "647--668",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - EVI1 splice variants modulate functional responses in ovarian cancer cells

AU - Dutta, Punashi

AU - Bui, Tuyen

AU - Bauckman, Kyle A.

AU - Keyomarsi, Khandan

AU - Mills, Gordon

AU - Nanjundan, Meera

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Amplification of 3q26.2, found in many cancer lineages, is a frequent and early event in ovarian cancer. We previously defined the most frequent region of copy number increase at 3q26.2 to EVI1 (ecotropic viral integration site-1) and MDS1 (myelodysplastic syndrome 1) (aka MECOM), an observation recently confirmed by the cancer genome atlas (TCGA). MECOM is increased at the DNA, RNA, and protein level and likely contributes to patient outcome. Herein, we report that EVI1 is aberrantly spliced, generating multiple variants including a Del190-515 variant (equivalent to previously reported) expressed in >90% of advanced stage serous epithelial ovarian cancers. Although EVI1Del190-515 lacks ∼70% of exon 7, it binds CtBP1 as well as SMAD3, important mediators of TGFβ signaling, similar to wild type EVI1. This contrasts with EVI1 1-268 which failed to interact with CtBP1. Interestingly, the EVI1Del190-515 splice variant preferentially localizes to PML nuclear bodies compared to wild type and EVI1Del427-515. While wild type EVI1 efficiently repressed TGFβ-mediated AP-1 (activator protein-1) and plasminogen activator inhibitor-1 (PAI-1) promoters, EVI1Del190-515 elicited a slight increase in both promoter activities. Expression of EVI1 and EVI1Del427-515 (but not EVI1Del190-515) in OVCAR8 ovarian cancer cells increased cyclin E1 LMW expression and cell cycle progression. Furthermore, knockdown of specific EVI1 splice variants (both MDS1/EVI1 and EVI1Del190-515) markedly increased claudin-1 mRNA and protein expression in HEY ovarian and MDA-MB-231 breast cancer cells. Changes in claudin-1 were associated with alterations in specific epithelial-mesenchymal transition markers concurrent with reduced migratory potential. Collectively, EVI1 is frequently aberrantly spliced in ovarian cancer with specific forms eliciting altered functions which could potentially contribute to ovarian cancer pathophysiology.

AB - Amplification of 3q26.2, found in many cancer lineages, is a frequent and early event in ovarian cancer. We previously defined the most frequent region of copy number increase at 3q26.2 to EVI1 (ecotropic viral integration site-1) and MDS1 (myelodysplastic syndrome 1) (aka MECOM), an observation recently confirmed by the cancer genome atlas (TCGA). MECOM is increased at the DNA, RNA, and protein level and likely contributes to patient outcome. Herein, we report that EVI1 is aberrantly spliced, generating multiple variants including a Del190-515 variant (equivalent to previously reported) expressed in >90% of advanced stage serous epithelial ovarian cancers. Although EVI1Del190-515 lacks ∼70% of exon 7, it binds CtBP1 as well as SMAD3, important mediators of TGFβ signaling, similar to wild type EVI1. This contrasts with EVI1 1-268 which failed to interact with CtBP1. Interestingly, the EVI1Del190-515 splice variant preferentially localizes to PML nuclear bodies compared to wild type and EVI1Del427-515. While wild type EVI1 efficiently repressed TGFβ-mediated AP-1 (activator protein-1) and plasminogen activator inhibitor-1 (PAI-1) promoters, EVI1Del190-515 elicited a slight increase in both promoter activities. Expression of EVI1 and EVI1Del427-515 (but not EVI1Del190-515) in OVCAR8 ovarian cancer cells increased cyclin E1 LMW expression and cell cycle progression. Furthermore, knockdown of specific EVI1 splice variants (both MDS1/EVI1 and EVI1Del190-515) markedly increased claudin-1 mRNA and protein expression in HEY ovarian and MDA-MB-231 breast cancer cells. Changes in claudin-1 were associated with alterations in specific epithelial-mesenchymal transition markers concurrent with reduced migratory potential. Collectively, EVI1 is frequently aberrantly spliced in ovarian cancer with specific forms eliciting altered functions which could potentially contribute to ovarian cancer pathophysiology.

KW - Claudin-1

KW - Cyclin E1

KW - EMT

KW - EVI1

KW - Motility

KW - Ovarian cancer

KW - Splice variants

KW - TGFβ

UR - http://www.scopus.com/inward/record.url?scp=84878109215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878109215&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2013.02.008

DO - 10.1016/j.molonc.2013.02.008

M3 - Article

C2 - 23517670

AN - SCOPUS:84878109215

VL - 7

SP - 647

EP - 668

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 3

ER -